REGNRegeneron Pharmaceuticals, Inc.
# 78 · $805.02 (-1.72%) · $82.88B · Healthcare
Rango 52 semanas
Datos de mercado
- P/E
- 19.91
- 1M
- +1.13%
- 1A
- +40.55%
- Rentab.
- 0.46%
- RSI
- 74.04
- MACD
- +0.91%
Desglose
Por qué
- P/E of 19.9
- profit margin of 27.9%
- 12-1 momentum return of 39.0%
- trading 9.6% above 200d SMA
- MACD histogram positive
- EPS vs. estimates: +18.9% on average
El razonamiento lo genera el motor de scoring (en inglés).
Piotroski F-Score
5
5 / 9 checks superados
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Señales de riesgo
- Deteriorating fundamentalsMedia
gross margin and ROA both lower than the previous fiscal year
- Product revenue concentrationInfo
51% of revenue from Collaboration Revenue
Análisis de la empresa
Business Overview Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes prescription biologic medicines, generating revenue primarily from net product sales (e.g., EYLEA HD®, EYLEA®, LIBTAYO®) and from collaboration revenue (notably profit-share economics tied to Dupixent® and other antibodies sold with partners such as Sanofi and Bayer). Market Position Regeneron is a major innovator in antibody-based therapeutics, with durable scale in retina and immunology/oncology supported by integrated R&D and biologics manufacturing; a meaningful portion of earnings is also driven by partnered franchises where Regeneron participates via profit share/royalties rather than booking full end-market sales. Key Segments Regeneron reports one operating segment, encompassing all activities related to the discovery, development, and commercialization of medicines for serious diseases.
Resumen generado por IA a partir de datos de terceros; puede contener errores. No constituye asesoramiento financiero ni recomendación de inversión.
Periodo: 2021-12-31 → 2025-12-31
Un guion (—) indica que el dato no está disponible para ese ejercicio, no que sea cero. Aquí no se estima ni se rellena nada.